corporate overview


investors & media


investors & media

Investor Relations Home

Rigel currently has five product candidates in development: fostamatinib, an oral SYK inhibitor expected to enter Phase 3 clinical trials for ITP and a Phase 2 clinical trial for IgA Nephropathy in 2014; R348, a topical JAK/SYK inhibitor for chronic dry eye currently in Phase 2 clinical trials; R118, an AMPK activator in Phase 1; and two oncology product candidates in Phase 1 development with partners BerGenBio and Daiichi Sankyo.
Stock Quote
RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.06 (1.74%)
Data as of 07/24/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
2014 Q1 10-Q - PDF 
2014 Q1 10-Q
2013 Annual Report - PDF 
2013 Annual Report
Financial Tear Sheet - PDF 
Financial Tear Sheet
Recent NewsMore >>
07/16/14Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
SOUTH SAN FRANCISCO, Calif., July 16, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura). The focus of these clinical studies is to evaluate the potential of fostamatinib to increase the platelet counts of patients with chronic ITP. Fostamatinib may provide a novel therapeutic for the underlying cause of this autoimmune disease... 
Printer Friendly Version
05/29/14Rigel to Present at Jefferies 2014 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Jefferies 2014 Global Healthcare Conference in New York City on Tuesday, June 3rd at 2:30 p.m. ET. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to th... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Most Viewed Links
Updated 07/25/14
1.Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
2.SEC Filings
3.Rigel Announces Publication of R118 AMPK Activator Research
4.Rigel Announces First Quarter 2014 Financial Results
5.Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference
* Data collected 07/17/14 - 07/24/14
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
© 2014 Rigel  |  privacy  |  disclaimer  | Follow Us On:contact us | site map |  search    Search